Trial Profile
Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of the EORTC ROG and GUCG
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; Bicalutamide; Flutamide; Goserelin; Leuprorelin; Triptorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PEGASUS
- 02 Apr 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2026.
- 13 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 30 May 2021 This trial has been suspended in Spain, according to European Clinical Trials Database record.